AIEQ · Exit · 1d
weight 0.300% → 0 (exited)·stock up 7.9% in the 30 days before
Jul 1·entry $159.79·now $159.12
-0.42%
since Jul 1
PODD
GrowthINSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
Close · 3M
-34.20%
Held by 0 AI ETFs
None of the tracked AI ETFs currently hold this name.
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals4
Win rate75% (3/4)
Avg buy return-0.18%
AIEQ · Weight increase · 3d
weight 0.280% → 0.310% (+0.030 pp)·stock up 8.4% in the 30 days before
Jun 28·entry $157.74·now $159.12Fresh
+0.87%
since Jun 28
AIEQ · Weight increase · 2d
weight 0.280% → 0.300% (+0.020 pp)·stock up 8.4% in the 30 days before
Jun 26·entry $158.25·now $159.12Fresh
+0.55%
since Jun 26
AIEQ · Weight decrease · 2d
weight 0.310% → 0.290% (-0.020 pp)·stock up 0.6% in the 30 days before
Jun 12·entry $149.70·now $159.12
+6.29%
since Jun 12
AIEQ · Weight increase · 2d
weight 0.270% → 0.300% (+0.030 pp)·stock up 1.3% in the 30 days before
Jun 7·entry $151.51·now $159.12Drifting
+5.02%
since Jun 7
AIEQ · New entry · 1d
weight 0 → 0.050% (new)·stock down 15.5% in the 30 days before
May 3·entry $171.39·now $159.12Fresh
-7.16%
since May 3
PQUS · Exit · 1d
weight 0.180% → 0 (exited)·stock up 0.6% in the 30 days before
Jun 12·entry $149.70·now $159.12
+6.29%
since Jun 12
PQUS · Weight decrease · 3d
weight 0.180% → 0.140% (-0.040 pp)·stock down 18.0% in the 30 days before
Apr 30·entry $172.14·now $159.12
-7.56%
since Apr 30
PQUS · Weight decrease · 2d
weight 0.180% → 0.160% (-0.020 pp)·stock down 23.1% in the 30 days before
Apr 29·entry $160.02·now $159.12
-0.56%
since Apr 29
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jun 28
The AI ETF AIEQ is showing a weight increase trend for Insulet Corp, indicating a positive view and accumulation of shares. This action directly contrasts with the framework's 'Fail' verdict, which is primarily driven by a lack of complete financial health data and the absence of a clear margin of safety at the current valuation.
- Circle of CompetenceThe company's focus on a recurring-revenue medical device for a chronic condition offers reasonable predictability for unit economics and long-term cash flows, despite industry innovation.
- Economic MoatThe company benefits from switching costs for patients and healthcare providers, a recognized brand in a critical medical device niche, and intellectual property protection and regulatory hurdles for new entrants.
- ManagementInsufficient information is available to assess management's candor, capital allocation discipline, or extent of skin in the game.
- Financial HealthThe provided financials are insufficient to assess a 10-year average ROE, operating margin stability, debt manageability, or owner earnings, preventing a conclusive evaluation of financial health against the framework's criteria.
- Margin of SafetyThe current valuation metrics, including a PER of 32.91 and PBR of 13.2, do not suggest a clear defensible discount to intrinsic value, making a sufficient margin of safety unlikely.
While Insulet Corp appears to operate within a predictable circle of competence and possesses a durable economic moat, a full assessment of its financial health and management practices is hindered by insufficient data. Crucially, the current valuation, marked by high multiples, does not present a discernible margin of safety under this investment framework.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.